Shifting the limits of resuscitation with “CIRD Controlled Integrated Resuscitation Device” (CIRDinnova)
Only 3% of the patients survive out-of-hospital resuscitation, and only 18% survive in-hospital resuscitation. In order to increase survival, a therapy was developed named CARL: Controlled Automated Reperfusion of the whoLe body. In this project, the technology is further developed from TRL 7 towards TRL 9.
Bringing the CARL therapy towards the market, resulting in improved survival rates and better quality of life for survivors after resuscitation.
More detailed information
Dinis Dos Reis Miranda
Role Erasmus MC:
Horizon 2020 Fast Track to Innovation Pilot